자가 주사기 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the self-injection devices market size was valued at USD 25.22 billion in 2025 and estimated to grow from USD 27.87 billion in 2026 to reach USD 45.88 billion by 2031, at a CAGR of 10.49% during the forecast period (2026-2031).

This report is Segmented by Product (Pen Injectors, Auto-Injectors, Wearable Injectors, and Needle-Free Injectors), Usage (Disposable and Re-Usable), Application (Diabetes & Other Hormonal Disorders, Auto-Immune Diseases, and More), Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Self-injection Device Market Trends and Insights

Rising Prevalence of Chronic Diseases

More than 537 million adults live with diabetes and cancer incidence has climbed 47% since 2000; these figures create a sustained pull for at-home injection therapies. Insulet's SmartAdjust clearance in August 2024 illustrates regulators' support for automated insulin delivery platforms that lower facility pressure while enabling multidisease care. Pharmaceutical pipelines now bundle agents addressing comorbidities into single high-viscosity formulations deliverable via connected autoinjectors, improving adherence and containing costs borne by payers. Ageing demographics in Europe, North America, and parts of Asia amplify the long-run influence of this driver.

Increasing Patient Preference For Home Healthcare

Pandemic-era exposure to telehealth strengthened demand for self-administration tools that offer privacy and flexibility. Coherus BioSciences' UDENYCA ONBODY came to market in February 2024, letting neutropenia patients avoid a second clinic visit for pegfilgrastim. Real-time adherence monitoring and dosing feedback delivered through Bluetooth-enabled pen injectors lessen safety concerns and align with payers' desire to shift care outside hospitals. Younger cohorts comfortable with digital interfaces now expect connected devices as standard rather than premium features, supporting mid-term growth.

Stringent Regulatory & Quality Compliance Requirements

The European Parliament's October 2024 vote to revise MDR deadlines showed how certification backlogs can stall product introductions and inflate compliance costs, which can top USD 50 million for a globally launched combination product. The FDA treats on-body injectors as Class II devices subject to special performance controls, adding design-verification layers that can lengthen timelines by 18 months. Smaller innovators often lack the capital for parallel submissions across regions, consolidating power among larger companies with dedicated regulatory teams.

Other drivers and restraints analyzed in the detailed report include:

1. Expansion of Biologic & Biosimilar Therapeutics
2. Advancements in drug-device combination technologies
3. Availability of Alternative Drug-Delivery Modalities

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Pen injectors generated the highest revenue, holding 47.12% self-injection devices market share in 2025, supported by mature manufacturing infrastructure and clinician familiarity. The self-injection devices market size for pens is projected to reach USD 19.13 billion by 2031 at a steady 8.27% CAGR. Wearable injectors, however, outpace every other product class at a 12.21% rate as biologic concentrations and volumes rise. Stevanato Group's Vertiva on-body system dispenses up to 10 mL over several minutes, lending itself to oncology and rare-disease regimens once limited to intravenous infusion. Auto-injectors remain a resilient sub-segment, buoyed by biosimilar filtration of adalimumab and etanercept into primary care. Needle-free devices, although technologically compelling, still confront price and regulatory hurdles that curb immediate impact.

A second wave of innovation focuses on device connectivity. Bluetooth modules in wearable pumps transmit dosing logs to cloud dashboards, giving physicians granular adherence visibility. Pharmaceutical firms now bundle apps with devices to differentiate therapy packages and gather real-world evidence for health-technology assessments. As data architecture becomes integral, device makers are forced to build cybersecurity competencies alongside mechanical engineering capabilities, raising entry barriers for new entrants and intensifying collaboration needs between software and hardware teams.

Complete Report Scope:

• By Product
  • Pen Injectors
    • Disposable Pens
    • Re-usable Pens
  • Auto-injectors
    • Prefilled Disposable
    • Prefilled Re-usable
  • Wearable Injectors
    • Large-volume Patch Pumps
    • Bolus-on-demand Devices
  • Needle-Free Injectors
    • Spring-powered Jet
    • Gas-powered Jet
• By Usage
  • Disposable
  • Re-usable
• By Application
  • Diabetes & Other Hormonal Disorders
  • Auto-immune Diseases
  • Oncology
  • Pain Management
  • Other Applications
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America contributed 38.12% of global revenue in 2025 thanks to robust reimbursement, high biologic penetration, and early connected-device adoption. The region's self-injection devices market size is on track to grow 9.05% per year through 2031, supported by BD's expanded syringe-barrel capacity and the FDA's clear guidance on digital-health add-ons. Canada's health-technology assessments increasingly endorse connected autoinjectors for adherence improvement, while Mexico's maquiladora site expansions create a cost-efficient production corridor for export into the United States.

Asia-Pacific, expanding at an 11.21% CAGR, is propelled by China's National Medical Products Administration, which approved 12,213 devices in 2024, a gateway for local manufacturers scaling into global supply chains. India's contract-development organisations are pairing with European pharma to build fill-finish lines dedicated to GLP-1 pens, compressing lead times and costs. Japan, South Korea, and Australia combine mature reimbursement systems with ageing populations, creating immediate demand for high-end connected devices.

Europe sustains mid-single-digit growth as MDR compliance costs restrain smaller players even while harmonised rules simplify multi-country launches. Germany's sickness funds reimburse electromechanical pens when paired with outcomes-based contracts that cap payer risk. The UK's National Institute for Health and Care Excellence (NICE) has invited real-world evidence generated by connected autoinjectors into cost-effectiveness files, a move expected to encourage broader digital uptake across the bloc. Eastern European markets remain cost-sensitive but are adopting disposable pens for biosimilar adalimumab at faster clips than Western peers.

South America and the Middle East & Africa are at earlier stages, yet rising chronic-disease incidence and public-sector procurement reforms point to higher volumes over the decade. Brazil's national immunisation plan has already earmarked budget for 3 mL prefilled devices to support oncology biosimilars, while Saudi Arabia's Vision 2030 healthcare push fast-tracks registration of patient-centric devices.

1. Beckton Dickinson
2. Gerresheimer
3. Insulet Corp.
4. Ypsomed
5. West Pharmaceutical Services
6. SHL Medical
7. Owen Mumford
8. Recipharm
9. Halozyme
10. Novo Nordisk
11. Eli Lilly and Company
12. Sanofi
13. Roche
14. Amgen
15. Teva Pharmaceutical Industries
16. Bespak by Recipharm
17. Nemera
18. Phillips-Medisize (Molex)
19. Haselmeier GmbH
20. Medtronic

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Prevalence of Chronic Diseases
  • 4.2.2 Increasing Patient Preference For Home Healthcare
  • 4.2.3 Expansion of Biologic And Biosimilar Therapeutics
  • 4.2.4 Advancements In Drug-Device Combination Technologies
  • 4.2.5 Supportive Reimbursement and Cost-Containment Policies
  • 4.2.6 Growing Investments From Pharma and Medtech Partnerships
• 4.3 Market Restraints
  • 4.3.1 Stringent Regulatory and Quality Compliance Requirements
  • 4.3.2 Availability of Alternative Drug Delivery Modalities
  • 4.3.3 High Upfront Device Development And Manufacturing Costs
  • 4.3.4 Concerns Over Safety, Needle Anxiety, And User Errors
• 4.4 Regulatory Landscape
• 4.5 Porter's Five Forces Analysis
  • 4.5.1 Threat of New Entrants
  • 4.5.2 Bargaining Power of Buyers
  • 4.5.3 Bargaining Power of Suppliers
  • 4.5.4 Threat of Substitutes
  • 4.5.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Product
  • 5.1.1 Pen Injectors
    • 5.1.1.1 Disposable Pens
    • 5.1.1.2 Re-usable Pens
  • 5.1.2 Auto-injectors
    • 5.1.2.1 Prefilled Disposable
    • 5.1.2.2 Prefilled Re-usable
  • 5.1.3 Wearable Injectors
    • 5.1.3.1 Large-volume Patch Pumps
    • 5.1.3.2 Bolus-on-demand Devices
  • 5.1.4 Needle-Free Injectors
    • 5.1.4.1 Spring-powered Jet
    • 5.1.4.2 Gas-powered Jet
• 5.2 By Usage
  • 5.2.1 Disposable
  • 5.2.2 Re-usable
• 5.3 By Application
  • 5.3.1 Diabetes & Other Hormonal Disorders
  • 5.3.2 Auto-immune Diseases
  • 5.3.3 Oncology
  • 5.3.4 Pain Management
  • 5.3.5 Other Applications
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East & Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East & Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
  • 6.3.1 Becton, Dickinson & Co.
  • 6.3.2 Gerresheimer AG
  • 6.3.3 Insulet Corp.
  • 6.3.4 Ypsomed AG
  • 6.3.5 West Pharmaceutical Services
  • 6.3.6 SHL Medical
  • 6.3.7 Owen Mumford Ltd.
  • 6.3.8 Recipharm AB
  • 6.3.9 Halozyme (Antares Pharma Inc)
  • 6.3.10 Novo Nordisk A/S
  • 6.3.11 Eli Lilly & Co.
  • 6.3.12 Sanofi
  • 6.3.13 Roche Diabetes Care
  • 6.3.14 Amgen Inc.
  • 6.3.15 Teva Pharmaceutical Industries
  • 6.3.16 Bespak by Recipharm
  • 6.3.17 Nemera
  • 6.3.18 Phillips-Medisize (Molex)
  • 6.3.19 Haselmeier GmbH
  • 6.3.20 Medtronic plc

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment